Seattle Genetics appoints Chris Boerner commercial SVP
This article was originally published in Scrip
Executive Summary
Seattle Genetics, a biotech company focused on the development and commercialisation of monoclonal antibody-based therapies for the treatment of cancer, has appointed Dr Chris Boerner senior vice-president, commercial. He replaces Bruce Seeley who is leaving the company to pursue other opportunities. Dr Boerner joined Seattle Genetics in 2010 as vice-president of marketing. Prior to that, he spent eight years at Genentech in a variety of commercial roles, including director of marketing on Avastin (bevacizumab).
You may also be interested in...
Almirall launches Constella in six European markets
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira raises $35m in series B
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis ups public offering to $240m
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.